Skip to main content
Ovarian Cancer
Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance
Read More
Ovarian Cancer
No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib in Women with Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer, PARP Inhibitors
PARP Inhibitors Do Not Significantly Increase Risk for Secondary Hematologic Malignancy
Read More
Ovarian Cancer
Safety of Approved Rucaparib Starting Dose Confirmed from Pooled Analysis
Read More
Ovarian Cancer
Phase 3 Study to Investigate Anti–PD-1 Antibody in the Treatment of High-Grade Ovarian Cancer
Read More
PARP Inhibitors
The Treatment Landscape in Ovarian Cancer: A Focus on PARP Inhibitors
Read More
PARP Inhibitors
The Treatment Landscape in Ovarian Cancer: A Focus on PARP Inhibitors
Read More
PARP Inhibitors
The Treatment Landscape in Ovarian Cancer: A Focus on PARP Inhibitors
Read More
Original Research, Adverse Events, Oncology Pharmacy Programs/Protocols
Pharmacist-Run Chemotherapy-Induced Nausea and Vomiting Management Protocol Improves Patient Outcomes and Benefits Physician Workflow
David M. Hughes, PharmD, BCOP, Renee L. Vose, PharmD, Bhavesh Shah, RPh, BCOP, Radhika Jhaveri, PharmD, BCOP
David M. Hughes, PharmD, BCOP; Renee L. Vose, PharmD; Bhavesh Shah, RPh, BCOP; Radhika Jhaveri, PharmD, BCOP
Read More
Original Research
Assessing the Impact of Limited Distribution Drug Networks Based on Time to Accessing Oral Oncolytic Agents at an Integrated Specialty Pharmacy
Houston Wyatt, PharmD, CSP, Megan Peter, PhD, Autumn Zuckerman, PharmD, BCPS, AAHIVP, CSP, Josh DeClercq, MS, Leena Choi, PhD, Samuel Starks, PharmD, Matthew Maulis, PharmD, Madan Jagasia, MBBS, MS
Houston Wyatt, PharmD, CSP; Megan Peter, PhD; Autumn Zuckerman, PharmD, BCPS, AAHIVP, CSP; Josh DeClercq, MS; Leena Choi, PhD; Samuel Starks, PharmD; Matthew Maulis, PharmD; Madan Jagasia, MBBS, MS
Read More
Page 132 of 200
Results 1311 - 1320 of 1993